Molecular Partners AG
NASDAQ:MOLNBiotechnology
Healthcare
$2.67 +0.77%
+$0.03 today
- Market cap
- $100.28M
- Beta
- 0.71
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.55
52W Low $3.41High $5.36
Volume 0.00M
Average 0.00M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$58.12M
FY 2025 · Annual
Net Income
-$61.65M
FY 2025 · Annual
Income Statement
CHF
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.33M | 189.56M | 7.04M | 4.97M | 0 |
| Cost of Revenue | 55.72M | 50.75M | 47.84M | 47.5M | 2.58M |
| Gross Profit | (46.39M) | 138.81M | (40.81M) | (42.53M) | (2.58M) |
| Gross Margin | -497.2% | 73.2% | -579.8% | -855.8% | — |
| Research & Development | 55.72M | 50.75M | 48.78M | 48.6M | 40.19M |
| Selling, General & Admin | 16.91M | 21.82M | 19M | 17.16M | 14.87M |
| Operating Expenses | 72.75M | 72.94M | 20.3M | 18.68M | 50.89M |
| Depreciation & Amortization | 2.57M | 2.39M | 2.42M | 2.37M | 2.14M |
| EBITDA | (60.66M) | 119M | (59.52M) | (51.65M) | (59.49M) |
| EBITDA Margin | -650.2% | 62.8% | -845.6% | -1039.2% | — |
| Operating Income | (63.42M) | 116.61M | (61.11M) | (61.22M) | (58.12M) |
| Operating Margin | -679.7% | 61.5% | -868.3% | -1231.7% | — |
| Interest Income | 108.28K | 1.2M | 4.28M | 3.38M | 1.52M |
| Interest Expense | 608.14K | 648.12K | 49K | 25K | 18K |
| Other Income / Expenses | (365K) | 1.24M | (876K) | 7.18M | (3.53M) |
| Income Before Tax | (63.78M) | 117.85M | (61.98M) | (54.04M) | (61.65M) |
| Pre-Tax Margin | -683.6% | 62.2% | -880.7% | -1087.3% | — |
| Income Tax Expense | 2K | 0 | 0 | 2K | 2K |
| Net Income | (63.79M) | 117.85M | (61.98M) | (54.04M) | (61.65M) |
| Net Margin | -683.7% | 62.2% | -880.7% | -1087.4% | — |
| EPS (Basic) | (2.06) | 3.63 | (1.89) | (1.59) | (1.65) |
| EPS (Diluted) | (2.06) | 3.54 | (1.89) | (1.59) | (1.65) |
| 31.01M | 32.47M | 32.77M | 34.03M | 37.27M | |
| 31.01M | 33.27M | 32.77M | 34.03M | 37.27M |
MOLN Earnings Waterfall · TTM
NASDAQ:MOLN · Revenue to Net Income
Key Ratios
EPS$-1.56
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$72.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.56, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Oct 29, 2026 | |
| 6-K | 6-K filing | Aug 25, 2026 | |
| 6-K | 6-K filing | Jul 20, 2026 | |
| 6-K | 6-K filing | Jul 7, 2026 | |
| 6-K | 6-K filing | Jul 2, 2026 |
How much revenue does MOLN generate?
Molecular Partners AG (MOLN) reported $0.00 of revenue in fiscal 2025.
Is MOLN profitable?
Molecular Partners AG (MOLN) reported -$61.65M of net income.
Continue the stock analysis
Jump to another research area for this company.